Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: www.intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

EsotericDark Aug. 31 at 5:03 PM

$INTS Decided to spend a little more time digging into this company this afternoon since I'm bored. Decided to dig into their SEC Filings in the past two months. I've talked at length before about the company being in an excellent position for a clinical stage biotech company. You can find this on my profile. From what I've seen, this company is more solid than almost every other company I've looked into in this sector at this point in time. Not only do they have partnerships with two of the biggest pharmaceutical companies in America with Merck (manufacturer of Keytruda) and Bristol-Myers Squibb (manufacturer of Opdivo and Abilify), as well as the National Cancer Institute - I've just learned that they have a partnership with the Swiss Cancer Institute too. Having collaborated with both Merck and the Swiss Cancer Institute on their clinical trials. Going to stick with this one for the next few months, unless something drastic happens. Reiterating my position of 70,000 Shares at 0.26

1 · Reply

RiZzBoTt Aug. 31 at 1:27 PM

$AMC plus there is the issue of massive debt, 0 retail interest and no buying pressure. This play is dead until it hits $2. $GME was the REAL squeeze play until shorts devised the greatest ruse in stock market history. They allowed AMC and other meme stocks run, the ol divide and conquer tactic, taking buying pressure and interest away from GME before pulling the rug and trapping millions of investors, killing any chance of a MOASS. And yes your ex hedge fund manager/CEO has been in on it since day one. And yall wonder why they call yall dumb money. Take your losses and dump them into a real squeeze candidate like $INTS. Don’t take my word for it though. Do your own research. IMO Easy 100% when it finally runs. You’ll thank me later.

1 · Reply

StockAuthority Aug. 31 at 12:58 AM

$INTS agreed. Some retail shorting last two days but staying short a biotech can be absolute suicide for you account as many wrecked trader stories through the years attest to. Timing for news is the question but this is a buy at this price for sure to me.

0 · Reply

basedman Aug. 30 at 10:55 PM

$INTS a phase 3 and a phase 2 in the pipeline. This will go. When it does is a shrug from me. Earliest catalyst Sep but Q4 in general more likely, expected news is secured non dilutive funding. This is a HODL until it pops stock for me and ignore the penny flipping.

1 · Reply

BpB12345 Aug. 30 at 4:04 PM

$INTS going to start position here this week

0 · Reply

StockAuthority Aug. 30 at 3:34 AM

$INTS my strong history of predicting huge bio winners has me very excited here.

1 · Reply

Jeanfleduc Aug. 30 at 3:00 AM

$INTS Come on $INTS cure cancer already! ;)

0 · Reply

DipBuyInvester Aug. 29 at 8:11 PM

$INTS CYCU in dip right now. Load the boat.

0 · Reply

DagZahav Aug. 29 at 7:50 PM

$INTS New to this stock, so nimble a little bit more at 0.285

0 · Reply

Rangodown Aug. 29 at 7:18 PM

$INTS how much does everyone believe in this stock seriously?

2 · Reply

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 24 days ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 27 days ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 3 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 3 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 3 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 4 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 4 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 6 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 7 months ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 8 months ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 9 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 10 months ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 10 months ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 10 months ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 10 months ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 10 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 1 year ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 1 year ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 1, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Nov 13, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

$Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023$

Nov 2, 2023, 7:01 AM EDT - 1 year ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Sep 7, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 5, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Aug 7, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

Jul 5, 2023, 4:15 PM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jul 1, 2023, 3:15 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Sizable Deals Close Out The Q2 IPO Market, Led By Thrift Store Savers

AENT FIHL GENK KGS SRFM SVV VTMX

Jun 29, 2023, 8:00 PM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jun 6, 2023, 7:35 AM EDT - 2 years ago

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

$Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas$

Jun 3, 2023, 8:00 AM EDT - 2 years ago

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Dec 8, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Nov 18, 2022, 7:01 AM EST - 3 years ago

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

EsotericDark Aug. 31 at 5:03 PM

1 · Reply

RiZzBoTt Aug. 31 at 1:27 PM

1 · Reply

StockAuthority Aug. 31 at 12:58 AM

0 · Reply

basedman Aug. 30 at 10:55 PM

1 · Reply

BpB12345 Aug. 30 at 4:04 PM

$INTS going to start position here this week

0 · Reply

StockAuthority Aug. 30 at 3:34 AM

$INTS my strong history of predicting huge bio winners has me very excited here.

1 · Reply

Jeanfleduc Aug. 30 at 3:00 AM

$INTS Come on $INTS cure cancer already! ;)

0 · Reply

DipBuyInvester Aug. 29 at 8:11 PM

$INTS CYCU in dip right now. Load the boat.

0 · Reply

DagZahav Aug. 29 at 7:50 PM

$INTS New to this stock, so nimble a little bit more at 0.285

0 · Reply

Rangodown Aug. 29 at 7:18 PM

$INTS how much does everyone believe in this stock seriously?

2 · Reply

LogicalTrading Aug. 29 at 7:04 PM

$APDN next $IPDN in the making — swung $SMX two times already — back in below 1.95 going into Tuesday — still holding $INTS — all BIG moves going into Labor Day 🍻

1 · Reply

StockAuthority Aug. 29 at 7:02 PM

$INTS just one PR away from running like $IPDN imo :-)

0 · Reply

StockAuthority Aug. 29 at 6:12 PM

$INTS INTS price target $4.5 and trades .28s I love the potential for $IXHL style move here $INTS INT230-6, is advancing in a Phase 3 INVINCIBLE-3 sarcoma study and a Phase 2 INVINCIBLE-4 breast cancer study, with early data showing high tumor necrosis and a 100% complete response rate in preclinical MPNST models. $11.3 million raised in 2025 extending its cash runway into H2 2026, Intensity is actively addressing funding constraints for INVINCIBLE-3 through potential partnerships or non-dilutive financing, which could act as significant catalysts in September 2025 or Q4. The stock’s low market cap ($14.31M) and analyst Strong Buy rating with a $4.50 target suggest substantial upside potential, while Fast Track and Orphan Drug designations enhance regulatory prospects.

0 · Reply